Phaseline

Targets › CD274

CD274 (Programmed cell death 1 ligand 1): drug programs, companies and trials

83 programs from 64 companies in 990 trials: 590 Phase 2, 232 Phase 1, 136 Phase 3, 32 Phase 4; Oncology, Other, Infectious disease; next expected readout Nov 2026.

Plays a critical role in induction and maintenance of immune tolerance to self. As a ligand for the inhibitory receptor PDCD1/PD-1, modulates the activation threshold of T-cells and limits T-cell effector response. (UniProt, Q9NZQ7)

Open in Phaseline: the race on CD274, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Mayo ClinicBCG Solution
Glucagon-like peptide 1 receptor agonist
GLP1R, Ion channels, CD38, OPRM1, PDCD1, CD274Phase 4Pain, Postoperative; Limb Pain, Phantom; Healthy; Respiratory Function Loss …Nov 2026
M.D. Anderson Cancer Center[18F]-4FN
PARP 1, 2 and 3 inhibitor
PARP1, PARP3, PARP2, CHRNB2, CHRNA4, Tubulin, OPRM1, CD274Phase 4Lymphoma; Tobacco Use Cessation; Cigarette Smoking-Related Carcinoma; Hematopoietic and Lymphoid Cell Neoplasm …Dec 2026
Shanghai Pulmonary Hospital, Shanghai, ChinaPD-1/PD-L1 inhibitor
PD-1/PD-L1 pathway inhibitor; anti-PD-1 or anti-PD-L1 monoclonal antibody
PDCD1, CD274Phase 4NSCLC (Non-small Cell Lung Cancer)Oct 2028
RocheAtezolizumab
Programmed cell death 1 ligand 1 inhibitor
CD274Phase 3Non-Small Cell Lung Cancer; Hepatocellular Carcinoma; Muscle-invasive Bladder Cancer; Unresectable Hepatocellular Carcinoma …Nov 2026
Merck KGaAAvelumab
Programmed cell death 1 ligand 1 other
CD274Phase 3Solid Tumors; Locally Advanced or Metastatic Urothelial Carcinoma; Bladder (Urothelial, Transitional Cell) Cancer Metastatic or Unresectable; HNSCC …Nov 2026
AstraZenecaDurvalumab (MEDI4736)
Programmed cell death 1 ligand 1 inhibitor
CD274Phase 3Non Small Cell Lung Carcinoma NSCLC; Hepatocellular Carcinoma; Small Cell Lung Cancer; Biliary Tract Cancer …Nov 2026
Suzhou Suncadia BiopharmaceuticalsAdebrelimab (SHR-1316)
Programmed cell death 1 ligand 1 inhibitor
CD274Phase 3Locally Advanced or Metastatic Urothelial Carcinoma; PD-L1-positive Locally Recurrent Unresectable or Metastatic Triple-negative Breast Cancer; Advanced Biliary Tract Cancer; Patients With Unresectable Locally Advanced or Metastatic Untreated Gastric or Gastroesophageal Junction Adenocarcinoma …Dec 2026
AkesoEnvafolimab (AK112)
Programmed cell death 1 ligand 1 binding agent
CD274Phase 3Triple-Negative Breast Cancer (TNBC); Advanced Squamous Non Small Cell Lung Cancer; Advanced Non-small-cell Lung Cancer; Colorectal Adenocarcinoma …Dec 2026
3D Medicines (Sichuan)Envafolimab (KN035)
Programmed cell death 1 ligand 1 binding agent
CD274Phase 3Non-small Cell Lung Cancer; Advanced Endometrial Cancer; Solid Tumor; Solid TumorsDec 2026
PfizerAvelumab
Programmed cell death 1 ligand 1 other
CD274Phase 3Advanced MalignanciesDec 2026
BiotheusPM8002
bispecific antibody targeting PD-L1 and VEGF
CD274, VEGFA, PDCD1LG2Phase 3SCLC; Triple Negative Breast Cancer(TNBC); NSCLC; Neuroendocrine Neoplasm …Jan 2027
University Hospital, BordeauxPD-1/PD-L1 ICI + VEGFR-TKI combination
PD-1/PD-L1 checkpoint inhibitor combined with VEGFR tyrosine kinase inhibitor
PDCD1, CD274, KDR, FLT1, FLT4Phase 3Metastatic Renal Cell CarcinomaJan 2027
GenmabAcasunlimab
Bispecific antibody that engages PD-L1 and 4-1BB
CD274, TNFRSF9Phase 3PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLCJul 2027
IO BiotechIO102-IO103
Dual peptide antigen cancer vaccine (IDO peptide antigen IO102 and PD-L1 peptide antigen I
IDO1, CD274Phase 3Metastatic MelanomaSep 2027
AmgenABP 206
PD-L1 inhibitor
CD274Phase 3MelanomaJan 2028
Shanghai Chia Tai Tianqing Pharmaceutical Technology DevelopmentTQB2868 Injection
PD-L1 and TGF-β dual antibody
CD274, TGFB1Phase 3Metastatic Pancreatic Ductal AdenocarcinomaMay 2028
Sun Yat-sen UniversityPD-1/PD-L1 inhibitors
PD-1 and PD-L1 checkpoint inhibitors
PDCD1, CD274Phase 3Non-small Cell Lung CancerJul 2028
UNICANCERReduced dose intensity of IO
Anti-PD-1, anti-PD-L1, or anti-CTLA-4 checkpoint inhibitor
PDCD1, CD274, CTLA4Phase 3Lung Cancer MetastaticMay 2029
Sun Yat-sen UniversityPD-1/PD-L1 immune checkpoint inhibitor
PD-1/PD-L1 immune checkpoint inhibitor
PDCD1, CD274Phase 3Locally Advanced Non-Small Cell Lung CancerJun 2029
Cancer Institute and Hospital, Chinese Academy of Medical SciencesAnti-PD-1/PD-L1 Antibody
PD-1/PD-L1 checkpoint inhibitor
PDCD1, CD274Phase 3Esophagus Cancer; Esophageal CancerDec 2030
Shanghai Pulmonary Hospital, Shanghai, ChinaPD-L1/VEGF Bispecific Antibody (PM8002)
PD-L1 and VEGF dual-targeting bispecific antibody
CD274, VEGFAPhase 3Locally Advanced Non-Small Cell Lung CancerDec 2033
Biocadprolgolimab
anti-PD-L1 monoclonal antibody
CD274Phase 3Melanoma–
Shanghai Henlius BiotechHLX43
anti-PD-L1 antibody-drug conjugate with topoisomerase I inhibitor payload
CD274Phase 2Nasopharyngeal Carcinoma (NPC); Non Small Cell Lung Cancer; Colorectal Cancer (CRC); Cervical Cancer …Nov 2026
National Cancer Institute (NCI)PD-L1 t-haNK cells
Engineered natural killer cells expressing PD-L1
CD274Phase 2Stage II Squamous Cell Carcinoma of the Head and NeckDec 2026
RenJi HospitalABSK043
PD-1/PD-L1 interaction inhibitor
PDCD1, CD274Phase 2HCC - Hepatocellular CarcinomaDec 2026
ETOP IBCSG Partners FoundationAnti-PD-L1 antibody
PD-L1 inhibitor
CD274Phase 2SCLC,Extensive StageDec 2026
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin PharmaceuticalBenmelstobart injection
Humanized monoclonal antibody targeting PD-L1
CD274Phase 2Non-Small Cell Lung CancerDec 2026
Hunan Cancer HospitalSugemalimab
Programmed cell death 1 ligand 1 binding agent
CD274Phase 2Carcinoma, Non-Small-Cell LungDec 2026
National Cancer Institute (NCI)Bintrafusp Alfa (M7824)
Programmed cell death 1 ligand 1 binding agent; Transforming growth factor beta binding agent
CD274, TGFB1, TGFB2, TGFB3Phase 2Thymic Epithelial Tumor; Cancer Of Prostate; Kaposi Sarcoma; Urothelial CancerDec 2026
Cancer Institute and Hospital, Chinese Academy of Medical Sciencesanti-PD-1 or PD-L1 antibody
PD-1/PD-L1 pathway inhibitor
PDCD1, CD274Phase 2Head and Neck CancerDec 2026
The Second Affiliated Hospital of Chongqing Medical Universityanti-PD-1/anti-PD-L1 antibody
PD-1/PD-L1 checkpoint inhibitor
PDCD1, CD274Phase 2Chronic Hepatitis BDec 2026
IO BiotechIO103
PD-L1 peptide
CD274Phase 2MelanomaJan 2027
ImmuneOncia TherapeuticsDanburstotug (IMC-001)
Programmed cell death 1 ligand 1 inhibitor
CD274Phase 2Extranodal NK/T-cell Lymphoma, Nasal Type; TMB-H; Subjects With Resectable and Localized Gastric CancerFeb 2027
Zhejiang Cancer HospitalPD-1/PD-L1 inhibitors
PD-1/PD-L1 checkpoint inhibitor
PDCD1, CD274Phase 2Adjuvant RadiotherapyMar 2027
University Health Network, TorontoABSK043
PD-L1 inhibitor
CD274Phase 2SarcomaMar 2027
Sun Yat-sen UniversityAdebelimab
Anti-PD-L1 monoclonal antibody
CD274Phase 2Resectable Mucosal MelanomaMar 2027
Sun Yat-sen UniversitySugemalimab
Programmed cell death 1 ligand 1 binding agent
CD274Phase 2Limited Stage Small Cell Lung CancerMar 2027
Cancer Institute and Hospital, Chinese Academy of Medical SciencesPD-1/PD-L1 inhibitors
PD-1/PD-L1 pathway inhibitor
PDCD1, CD274Phase 2Advanced Malignant Solid TumorApr 2027
West China HospitalPD-L1 antibody
PD-L1 immune checkpoint inhibitor
CD274Phase 2Hepato Cellular Carcinoma (HCC)Apr 2027
First People's Hospital of HangzhouPD-L1 inhibitor
PD-L1 pathway inhibitor
CD274Phase 2Non-Small Cell Lung CancerApr 2027
ImmunityBioPD-L1 t-haNK
PD-L1-targeted human aNK cell therapy
CD274, PDCD1LG1Phase 2Pancreatic Cancer; Non-Small Cell Lung Cancer; Glioblastoma; Head and Neck CancerMay 2027
Fudan UniversityPD-L1/PD-1 inhibitor and chemotherapy
PD-L1/PD-1 checkpoint inhibitors combined with chemotherapy
PDCD1, CD274Phase 2NSCLC Stage IVJul 2027
Jinling Hospital, ChinaPD-1/PD-L1 ICI + VEGFR-TKI
PD-1/PD-L1 checkpoint inhibitor combined with VEGFR tyrosine kinase inhibitor
PDCD1, CD274, KDRPhase 2Renal Cell Carcinoma (RCC)Aug 2027
Shenyang Sunshine PharmaceuticalSSGJ-706
PD-1/PD-L1 bispecific antibody
PDCD1, CD274Phase 2First-line Advanced NSCLC PatientsAug 2027
Shanghai Hengrui PharmaceuticalAdebrelimab (SHR-1316)
Programmed cell death 1 ligand 1 inhibitor
CD274Phase 2Limited-stage Small-cell Lung Cancer; Malignant Solid Tumors; Advanced or Metastatic Non-small Cell Lung Cancer; Locally Advanced or Metastatic Pancreatic Cancer With …Oct 2027
Eye & ENT Hospital of Fudan UniversityFinolizumab
PD-L1 inhibitor
CD274Phase 2Hypopharyngeal CarcinomaNov 2027
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical Schoolbenmelstobart
PD-L1 inhibitor
CD274Phase 2Advanced Metastatic Pancreatic CancerDec 2027
Tianjin Medical University Cancer Institute and HospitalTQB2450
anti-PD-L1 monoclonal antibody
CD274Phase 2Non-small-cell Lung CancerDec 2027
Henan Cancer HospitalEnvorimab
PD-L1 inhibitor
CD274Phase 2Esophageal Malignant Neoplasm PrimaryDec 2027
Shanghai Pulmonary Hospital, Shanghai, ChinaSugemalimab
Programmed cell death 1 ligand 1 binding agent
CD274Phase 2Lung Cancer (NSCLC)Dec 2027
Chuangzhen ChenPD-1/PD-L1 monoclonal antibodies
PD-1/PD-L1 checkpoint inhibitor
PDCD1, CD274Phase 2RadiotherapyJan 2028
Changhai Hospitaltuvonralimab
PD-L1 inhibitor
CD274Phase 2MSS-type Low Rectal Cancer,Neoadjuvant Chemoradiotherapy, QL1706Aug 2028
City of Hope Medical CenterAnti-PD-L1 Monoclonal Antibody
PD-L1 inhibitor
CD274Phase 2Lung Non-Small Cell CarcinomaOct 2028
Second Affiliated Hospital of Guangzhou Medical UniversityPD-L1 antibody
PD-L1 immune checkpoint inhibitor
CD274Phase 2Lung CancerDec 2028
The First Affiliated Hospital with Nanjing Medical UniversityPD-1/PD-L1 monoclonal antibody
PD-1/PD-L1 pathway inhibitor
PDCD1, CD274Phase 2Primary Central Nervous System Lymphoma (PCNSL)Dec 2028
Second Affiliated Hospital of Guangzhou Medical UniversityPD-1/PD-L1/CTLA-4 inhibitors
PD-1, PD-L1, and CTLA-4 checkpoint inhibitors
PDCD1, CD274, CTLA4Phase 2Head/Neck NeoplasmJan 2029
Fudan UniversityAdebelimab
Anti-PD-L1 monoclonal antibody
CD274Phase 2Advanced HER2-positive Breast CancerFeb 2029
Tianjin Medical University Second HospitalPD-1/PD-L1 Inhibitor
PD-1/PD-L1 checkpoint inhibitor
PDCD1, CD274Phase 2Bladder (Urothelial, Transitional Cell) CancerMar 2029
UNC Lineberger Comprehensive Cancer CenterPD-1/PD-L1 inhibitor monotherapy
PD-1 or PD-L1 checkpoint inhibitor
PDCD1, CD274Phase 2Lung CancerJan 2033
University of California, DavisSystemic (ICI)-based therapy informed by PROphet CB assay and CARG-TT assessment
anti-PD(L)1 immune checkpoint inhibitor(s), with regimen selection guided by proteomic (PR
PDCD1, CD274Phase 2Non-small Cell Lung Cancer Stage IIICMay 2036
Hunan Province Tumor HospitalIBI318
Bispecific anti-PD-1/PD-L1 antibody
PDCD1, CD274Phase 2Non-Small Cell Lung Cancer–
Nanfang Hospital, Southern Medical UniversityPD-L1 inhibitor
PD-L1 inhibitor
CD274Phase 2Small Cell Lung Cancer Extensive Stage–
TILT BiotherapeuticsAvelumab
Programmed cell death 1 ligand 1 other
CD274Phase 1MelanomaDec 2026
Betta PharmaceuticalsBPI-371153
PD-L1 inhibitor
CD274Phase 1Advanced Solid TumorDec 2026
University of California, DavisIO102-IO103 Peptide Vaccine
PD-L1/IDO peptide vaccine activating T-cells against tumor and immune suppressive cells
CD274, IDO1Phase 1High Risk Non-Muscle Invasive Bladder Urothelial CarcinomaDec 2026
Sichuan Universityα-PD-L1/4-1BB DLL3 CAR-T (BHP01)
dual-targeted CAR-T cell therapy targeting PD-L1 and DLL3 with 4-1BB costimulatory domain
CD274, DLL3Phase 1Small Cell Lung Cancer Extensive StageDec 2026
China-Japan Friendship HospitalPD-1/L1 inhibitor
PD-1/PD-L1 pathway inhibitor
PDCD1, CD274Phase 1Advanced Solid TumorDec 2026
Sichuan UniversityDual-targeting VEGFR1/PD-L1 CAR-T cells
Bispecific CAR-T cells targeting VEGFR1 and PD-L1
FLT1, CD274Phase 1Malignant Peritoneal EffusionJun 2027
West China HospitalPD-1/PD-L1 Inhibitor-Based Therapy
PD-1/PD-L1 inhibitor monotherapy or combination therapy
PDCD1, CD274Phase 1Solid TumorsJul 2027
Sichuan UniversitySugemalimab
Programmed cell death 1 ligand 1 binding agent
CD274Phase 1Lung CancerOct 2027
PfizerPF-08046054/SGN-PDL1V
anti-PD-L1 antibody-drug conjugate
CD274Phase 1Carcinoma, Non-Small-Cell LungJan 2028
M.D. Anderson Cancer CenterAnti-PD-1/PD-L1
PD-1/PD-L1 checkpoint inhibitor monoclonal antibodies
PDCD1, CD274Phase 1Advanced Malignant Solid NeoplasmFeb 2028
Shine-On BiomedicalSOA101
Nanobody-based trispecific antibody T cell engager targeting PD-L1/HLA-G/CD3
CD274, HLA-G, CD3EPhase 1Solid TumorsFeb 2028
Centre hospitalier de l'Université de Montréal (CHUM)Pulse radiotherapy combined with PD(L)-1 inhibitors
Pulsed radiotherapy combined with PD(L)-1 immune checkpoint inhibition
PDCD1, CD274Phase 1Non Small Cell Lung CancerJul 2028
VaccinexAvelumab
Programmed cell death 1 ligand 1 other
CD274Phase 1Metastatic Pancreatic AdenocarcinomaDec 2028
Shanghai Chest HospitalPD-L1 inhibitor
PD-L1 inhibitor
CD274Phase 1Non-Small Cell Lung CancerDec 2028
AP BiosciencesAP505
Anti-PD-L1 and Anti-VEGF antibody fusion protein
CD274, VEGFAPhase 1Advanced Solid Tumors–
AstraZenecaAtezolizumab (MEDI4736)
Programmed cell death 1 ligand 1 inhibitor
CD274Phase 1Ovarian–
Checkpoint TherapeuticsCosibelimab (CK-301)
Programmed cell death 1 ligand 1 inhibitor
CD274Phase 1Lung Neoplasms; Cutaneous Squamous Cell Carcinoma–
Sichuan UniversityDual-targeting CLDN18.2 and PD-L1 CAR-T cells
Dual-targeting CAR-T cells against CLDN18.2 and PD-L1
CLDN18, CD274Phase 1Advanced Solid Tumor–
InxMed (Shanghai)Erfonrilimab (KN046)
Cytotoxic T-lymphocyte protein 4 inhibitor; Programmed cell death 1 ligand 1 inhibitor
CTLA4, CD274Phase 1Pancreatic Cancer; Digestive System Cancers; HER2-positive Locally Advanced Resectable Gastric Cancer–
Shanghai Huaota BiopharmaceuticalHB0036
Anti-PD-L1 and anti-TIGIT bifunctional molecule
CD274, TIGITPhase 1Advanced Solid Tumor–
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.IMM2510
Anti-PD-L1/VEGF bispecific antibody fusion protein
CD274, VEGFAPhase 1Advanced Solid Tumors–

Conditions

Hepatocellular Carcinoma (36) Breast Cancer (20) Non-Small Cell Lung Cancer (16) Lung Cancer (13) Biliary Tract Cancer (11) Pancreatic Cancer (11) Non Small Cell Lung Cancer (11) Bladder Cancer (11) Hepatocellular Carcinoma (HCC) (9) Non-small Cell Lung Cancer (9) Lung Non-Small Cell Carcinoma (9) Intrahepatic Cholangiocarcinoma (9)

Modalities

small molecule (32), mixed (23), antibody (10), other (6), protein or peptide (2)

Companies

Sun Yat-sen University (4) Sichuan University (4) Cancer Institute and Hospital, Chinese Academy of Medical Sciences (3) Shanghai Pulmonary Hospital, Shanghai, China (3) AstraZeneca (2) West China Hospital (2) Fudan University (2) Pfizer (2) National Cancer Institute (NCI) (2) M.D. Anderson Cancer Center (2) Second Affiliated Hospital of Guangzhou Medical University (2) University of California, Davis (2) IO Biotech (2) ImmuneOncia Therapeutics (1) Akeso (1) ETOP IBCSG Partners Foundation (1) Roche (1) Biotheus (1) Suzhou Suncadia Biopharmaceuticals (1) Shine-On Biomedical (1)

Related targets

PDCD1 (26) VEGFA (4) CTLA4 (3) KDR (2) FLT1 (2) TGFB1 (2) OPRM1 (2) IDO1 (2) PDCD1LG2 (1) HLA-G (1) CD3E (1) FLT4 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.